A new AstraZeneca drug has failed to extend significantly the lives of breast cancer patients in a blow to the company’s ambitions to hit an $80bn revenue target by 2030.

AstraZeneca’s lung cancer drug datopotamab deruxtecan, also called Dato-DXd, failed to show a significant benefit to overall survival when compared to standard chemotherapy drug docetaxel ...

AstraZeneca said on Monday its experimental precision drug developed with Japan's Daiichi Sankyo did not significantly improve overall survival for patients with a type of breast cancer in a late ...

(Reuters) - London-listed shares of AstraZeneca fell on Tuesday after results from the company's lung cancer trials showed that its experimental precision drug did not significantly improve ...

AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody-drug conjugate (ADC) has again failed to improve overall survival (OS) in a phase 3 trial. The latest miss happened in breast cancer, a ...

Monday, AstraZeneca Plc (NASDAQ:AZN) released high-level results from the TROPION-Breast01 Phase 3 trial of datopotamab deruxtecan (Dato-DXd) compared to the investigator’s choice of chemotherapy.

AstraZeneca said its breast cancer drug candidate showed positive results in a late stage trial, with improved progression-free survival in patients. The British pharma giant said Wednesday that ...

This three-drug combination is a standard first-line treatment for metastatic HER2-positive breast cancer. AstraZeneca and Daiichi Sankyo said the improvement in progression-free survival was ...

Amgen's positive lung cancer data: The company's drug, Imdelltra, reduced the risk of death by 40% compared to chemotherapy for small cell lung cancer patients whose disease had worsened after an ...

AstraZeneca revealed its experimental breast cancer drug did not succeed in prolonging the survival of patients with the disease. Britain's largest pharmaceutical business said the trial focused ...